U.S. stock night trading fluctuations: Akari Therap rose 3.65% in night trading, with active capital flow, and sector trends triggered volatility attention

U.S. Stock Night Market Movements

Akari Therap rose 3.65% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Recursion rose 1.62% in the night market. Based on recent key news:

1. On December 1, Recursion Pharmaceuticals announced a webinar on December 8 to discuss clinical data of REC-4881 in familial adenomatous polyposis. This news may attract market attention to the company's R&D progress, driving up the stock price. Source: Reuters

2. On December 2, company director Borgeson Blake submitted Form 144, planning to sell 220,000 shares of restricted securities. This move may raise market attention to the company's insider trading, affecting stock price volatility. Source: SEC announcement

3. On December 1, the company released relevant information through GlobeNewswire, emphasizing its responsibility for content. This may enhance investor confidence in the company's information transparency, supporting the stock price increase. Source: GlobeNewswire The U.S. stock market has seen increased volatility recently, and risks need to be monitored.

Moderna rose 0.42% in the night market. Based on recent key news:

1. On December 1, FDA officials accused the COVID-19 vaccine of being linked to child deaths, leading to increased market concerns about vaccine safety, causing Moderna's stock price to drop by 3.5%. This incident has sparked calls for vaccine transparency, affecting investor confidence.

2. On December 2, the FDA announced new restrictions on the vaccine market, further suppressing Moderna's stock price. This move may impact Moderna's market share and future revenue expectations.

3. On December 2, although Moderna's third-quarter performance exceeded expectations, a decline in vaccine demand led to a significant year-on-year drop in product revenue, resulting in poor stock performance. Analysts rate Moderna as "hold," but expect significant upside potential. The decline in vaccine demand has intensified market volatility.

JSPR fell 8.86% in the night market. Based on recent key news:

1. On December 2, Jasper Therapeutics announced positive preliminary data from the ETESIAN study, showing that briquilimab reduces airway reactivity and eosinophils in asthma patients. This news supports the further development of briquilimab in asthma treatment; however, the stock price still declined.

2. On December 2, the BEACON study found that the unusual efficacy in U.S. patients was due to misdiagnosis rather than drug issues. Briquilimab has shown strong safety and efficacy in other groups, supporting its further development On December 2nd, Jasper Therapeutics announced that it will discuss research results in a conference call and webinar. Despite the positive research results, the market reaction was poor, and the stock price fell. The biotechnology industry has been volatile recently and requires attention